ImmunityBio (IBRX) Revenue (2014 - 2026)
ImmunityBio (IBRX) reported Revenue of $44.2 million for Q1 2026, up 167.64% year-over-year from $16.5 million in Q1 2025, and up 15.47% on a QoQ basis from $38.3 million in Q4 2025.
ImmunityBio (IBRX) has 13 years of Revenue data on file, last reported at $44.2 million in Q1 2026.
- Quarterly Revenue rose 167.64% year-over-year to $44.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $141.0 million (up 351.53% YoY) and the FY2025 annual result came in at $113.3 million, up 668.31% from the prior year.
- Revenue improved to $44.2 million in Q1 2026 per IBRX's latest filing, from $38.3 million in the prior quarter.
- Across five years, Revenue topped out at $44.2 million in Q1 2026 and bottomed at $14000.0 in Q1 2022.
- The 5-year median for Revenue is $360000.0 (2023), against an average of $10.2 million.
- The widest annual swing landed in 2022, when Revenue slumped 89.93%; it then surged 41192.5% in 2025.
- Tracing IBRX's Revenue over 5 years: stood at $73000.0 in 2022, then jumped by 90.41% to $139000.0 in 2023, then jumped by 5333.09% to $7.6 million in 2024, then jumped by 406.95% to $38.3 million in 2025, then gained by 15.47% to $44.2 million in 2026.
- Per Business Quant, the three latest IBRX Revenue figures stand at $44.2 million (Q1 2026), $38.3 million (Q4 2025), and $32.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 306.30 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 2.99 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 3.61 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.17 Bn |
| 10 | ImmunityBio | 7.72 Bn | 7.34 Bn | 43.97 Mn | 44.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 44.21 Mn |
| Dec 31, 2025 | 38.29 Mn |
| Sep 30, 2025 | 32.06 Mn |
| Jun 30, 2025 | 26.43 Mn |
| Mar 31, 2025 | 16.52 Mn |
| Dec 31, 2024 | 7.55 Mn |
| Sep 30, 2024 | 6.11 Mn |
| Jun 30, 2024 | 1.05 Mn |
| Mar 31, 2024 | 40,000.00 |
| Dec 31, 2023 | 139,000.00 |
| Sep 30, 2023 | 82,000.00 |
| Jun 30, 2023 | 41,000.00 |
| Mar 31, 2023 | 360,000.00 |
| Dec 31, 2022 | 73,000.00 |
| Sep 30, 2022 | 118,000.00 |
| Jun 30, 2022 | 35,000.00 |
| Mar 31, 2022 | 14,000.00 |
| Dec 31, 2021 | 390,000.00 |
| Sep 30, 2021 | 66,000.00 |
| Jun 30, 2021 | 339,000.00 |
| Mar 31, 2021 | 139,000.00 |
| Dec 31, 2020 | 21,000.00 |
| Sep 30, 2020 | 151,000.00 |
| Jun 30, 2020 | 436,000.00 |
| Mar 31, 2020 | 165,000.00 |
| Dec 31, 2019 | 9,000.00 |
| Sep 30, 2019 | 12,000.00 |
| Jun 30, 2019 | 17,000.00 |
| Mar 31, 2019 | 5,000.00 |
| Dec 31, 2018 | 7,000.00 |
| Sep 30, 2018 | 31,000.00 |
| Jun 30, 2018 | 4,000.00 |
| Mar 31, 2018 | 5,000.00 |
| Dec 31, 2017 | 12,000.00 |
| Sep 30, 2017 | 8,000.00 |
| Jun 30, 2017 | 14,000.00 |
| Mar 31, 2017 | 11,000.00 |
| Dec 31, 2016 | 14,000.00 |
| Sep 30, 2016 | 12,000.00 |
| Jun 30, 2016 | 12,000.00 |
| Mar 31, 2016 | 6,000.00 |
| Dec 31, 2015 | 15,000.00 |
| Sep 30, 2015 | 10,000.00 |
| Jun 30, 2015 | 91,000.00 |
| Mar 31, 2015 | 120,000.00 |
| Dec 31, 2014 | 98,000.00 |
| Sep 30, 2014 | 133,000.00 |
| Jun 30, 2014 | 124,000.00 |
| Mar 31, 2014 | 286,000.00 |